CCL2 and myeloid sarcoma: Regarding the previously described biomarkers, studies were consistent with the validation of NAA predictive value for long-term disability in MS [93], and the association of MCP-1/CCL2 with active inflammation (based on MRI gadolinium-enhancing lesions and blood–brain barrier disruption).